Astellas Announces Updated Data from the Phase 1/2 CHRYSALIS Trial for Gilteritinib (ASP2215) in Patients with Relapsed or Refractory Acute Myeloid Leukaemia
Astellas Pharma Europe today announced that updated data from the Phase 1/2 CHRYSALIS trial, evaluating the safety, tolerability and efficacy of gilteritinib (ASP2215), an orally-administered inhibitor of FLT3/AXL in patients with relapsed or refractory (R/R) acute myeloid leukaemia (AML), were presented during an oral scientific session at the American Society of Hematology (ASH) 2015 annual meeting in Orlando.1 Preliminary data were presented at the 20th Congress of the European Hematology Association in June 2015 in Vienna, Austria.2
Gilteritinib has demonstrated inhibitory activity against FLT3 internal tandem duplication (ITD) as well as tyrosine kinase domain (TKD), two common types of FLT3 mutations that are seen in up to one-third of patients with AML.1
This updated analysis of the Phase 1/2 study included 169 patients with FLT3 mutations who were treated with ≥80 mg and more (up to 450 mg) of gilteritinib. A 53% overall response rate (ORR) was demonstrated regardless of prior therapy. Additionally, a 56% ORR was observed in patients who had a FLT3-ITD mutation, and 48% ORR was observed in patients who were treated with a tyrosine kinase inhibitor (TKI) prior to the study. Median overall survival was approximately 31 weeks (95% CI: 24–35). Treatment-related adverse events (AE) reported in ≥10% of the safety population included diarrhoea (16%), fatigue (13%), and aspartate aminotransferase (AST) increase (12%). Grade ≥3 QTc prolongation was reported in 3%. Serious adverse events that occurred in ≥10% of total subjects were febrile neutropenia (n=77; 31%), disease progression (n=32; 13%), and sepsis (n=30; 12%).1
“Long-term survival outcomes for patients of any age with acute myeloid leukemia (AML) using current treatments offer substantial room for improvement, and for patients with a mutation of the FLT3 gene, the need is even greater,” said Bob Löwenberg, M.D., professor of Hematology at Erasmus University Medical Center in Rotterdam Netherlands. “Promising therapies personalised to target specific biomarkers and with innovative mechanisms of action, such as gilteritinib, could change the outlook and prognosis for these patients.”
“We are pleased to see that gilteritinib demonstrates antileukaemic activity even in patients whose mutations have previously been associated with poor outcomes,” said Trial Investigator Jessica Altman, M.D. and associate professor of Haematology/Oncology at Northwestern University’s Feinberg School of Medicine.
“We live in an era of personalised medicine and targeted therapies, yet there is still a significant need for more effective AML treatments, particularly for patients with well-characterised FLT3 molecular defects,” said Erkut Bahceci, M.D. and executive medical director, Astellas. “Targeting both FLT3-ITD and FLT3-TKD mutations, as well as AXL, can potentially help avoid the acquired resistance seen with existing FLT3-ITD inhibitors and may increase duration of therapy.”
Notes to editors
About Acute Myeloid Leukaemia
Acute myeloid leukemia is a cancer that affects white blood cells and bone marrow.3 AML usually develops quickly, over days or weeks.3 It is most often diagnosed in older people, and is most common in people over 65 years old.3 The incidence of AML in European adults is 5-8 cases per 100,000.4 About two out of three AML patients who get standard induction chemotherapy with daunorubicin and cytarabine go into remission.5 The chance of remission depends to a large part on a person’s specific prognostic factors, such as age or the presence of certain gene or chromosome changes.5 Currently, available treatment options for R/R AML patients with FLT3 mutations are limited and prognosis is poor.6
Astellas Pharma Europe Ltd. operates in 40 countries across Europe, the Middle East and Africa, and is the regional business of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. The organisation’s focus is to deliver outstanding R&D and marketing to continue growing in the world pharmaceutical market. Astellas’ presence in Europe also includes an R&D site and three manufacturing plants. The company employs approximately 4,350 staff across these countries.
- Jessica K. Altman, Alexander E. Perl, Jorge Cortes et. al., Antileukemic Activity and Tolerability of ASP2215 ≥80 mg in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response. Study presented during an oral scientific session at the American Society of Hematology (ASH) 2015 annual meeting in Orlando, 6 Dec 2015
- Perl A, Altman J, Cortes J, et al. Results of a first in-human, Phase 1/2 trial of ASP2215, a selective, potent oral inhibitor of FLT3/AXL, in patients with relapsed or refractory acute myeloid leukaemia. 20th Congress of the European Hematology Association, Vienna, Austria. Presentation [Abstract No. S798]
- Cancer Research UK. The blood and acute myeloid leukaemia. Available at: http://www.cancerresearchuk.org/about-cancer/type/aml/about/the-blood-and-acute-myeloid-leukaemia (Last accessed June 2015)
- Patient UK. Acute Myeloid Leukaemia factsheet. Available at http://www.patient.co.uk/doctor/acute-myeloid-leukaemia-pro (Last accessed June 2015)
- American Cancer Society. Treatment response rates for acute myeloid leukemia. Available at: http://www.cancer.org/cancer/leukemia-acutemyeloidaml/detailedguide/leukemia--acute-myeloid--myelogenous--treating-response-rates. (Last accessed June 2015)
- Grunwald MR, Levis MJ. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. Int J Hematol 2013; 97(6):683-94
Emma White, +44 (0)7786 312623
Manager, Communications, EMEA
Red Door Unlimited
Laura Good, +44 (0)7889 757191
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00 | Pressemelding
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10 | Pressemelding
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13 | Pressemelding
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00 | Pressemelding
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41 | Pressemelding
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00 | Pressemelding
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i